http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106139160-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-537 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-537 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-08 |
| filingDate | 2016-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106139160-B |
| titleOfInvention | The maytansine prodrug of hyaluronic acid derivatization, preparation method and preparing the application in neoplasm targeted therapy drug |
| abstract | The invention discloses a kind of maytansine prodrug of hyaluronic acid derivatization, preparation method and preparing the application in neoplasm targeted therapy drug, including hyaluronic acid backbone, maytansine side chain；It is connected between the maytansine and hyaluronic acid by disulfide bond, the molecular weight of hyaluronic acid is 7 ~ 500 kDA；The content of maytansine is 10% ~ 50% in the maytansine prodrug of the hyaluronic acid derivatization.The maytansine prodrug of hyaluronic acid derivatization of the invention have it is amphipathic, Nano medication can be self-assembly of in aqueous solution, outer layer hydrophilic layer is made of hyaluronic acid, and inner hydrophobic layer is made of dewatering medicament maytansine.The maximum tolerance of anticancer drug can largely be improved；And there is active targeting ability without in addition modification targeted molecular, it is high in the accumulation rate of tumor locus, there is very high cytotoxicity to tumour cell, tumour growth can be good at inhibiting in therapeutic process in lotus tumour nude mouse. |
| priorityDate | 2016-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.